The Wuhan Institute of Biological Products Co Ltd was founded in September 1950 and is now affiliated with the China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group (Sinopharm), under the supervision of the State-owned Assets Supervision and Administration Commission of the State Council.

It is a large high-tech enterprise integrating the production, teaching, research and marketing of biological products and is one of the major production centers of biological products in China.

The institute is the guidance center for the national immunization program in Central and South China. It is the national engineering technology research center for vaccines, recognized by the Ministry of Science and Technology, as well as being one of the National Engineering Research Centers, recognized by the National Development and Reform Commission.

The institute covers an area of 36 hectares with registered capital of 1.06 billion yuan and total assets of more than 2.5 billion yuan.

It has nearly 1,000 employees, of whom more than 200 have master's degrees and doctorates, while employees with a bachelor's degree or above account for more than 60 percent of the total number of staff.

The institute was among the first batch of doctorate and master's degree-conferring bodies approved by the State Council, China's Cabinet and the only doctorate degree-conferring body in the biological products industry.

In 2010, the authorities gave their approval for the institute to set up a postdoctoral scientific research workstation, which has trained and offered many senior biotechnology experts positions in the biological products industry over the years.

In addition to completing the development and production tasks of vaccines under the national immunization program, the institute is also committed to research and development of innovative biological products, especially in the transformation and industrialization of products with strong potential.

Currently, the institute has research and production business covering three areas: vaccines, therapeutic preparations and diagnostic preparations. It has more than 70 products that have received mass production approval, including 12 vaccines and biological products that are being mainly marketed with an annual capacity of more than 120 million doses.

In recent years, through the establishment of three scientific research platforms -- for bioreactors, combined vaccines and humanized antibodies -- the institute has increased its investment in science and technology, created core technologies and accelerated independent innovation.

It has successively obtained support from national, provincial and Wuhan city-level key research projects and completed a number of new product research lines and development programs.

Related: Three COVID-19 vaccines approved for clinical trials